nach oben

European Radiology

Erschienen in:

01.12.2003 | Contrast Media

Currently used non-specific extracellular MR contrast media

verfasst von: M. F. Bellin, M. Vasile, S. Morel-Precetti

Erschienen in: European Radiology | Ausgabe 12/2003

Einloggen, um Zugang zu erhalten

Abstract

Magnetic resonance contrast agents have demonstrated their clinical usefulness in a variety of organs for improved detection of various neoplastic, inflammatory and functional abnormalities. Gadolinium chelates are the most widely used. They are extracellular, non-specific contrast agents. Their use in many clinical indications is justified because, in conjunction with improved imaging techniques, these safe and image-enhancing contrast agents add morphologic and functional information compared with unenhanced MR images. This article describes the commercially available compounds, and summarizes their approval status on the international market regarding indications and doses. Their mechanisms of action, biodistributions, toxicities and tolerance profiles in normal and high-risk patient populations are described. Additionally, this article reviews the specific recommendations by the manufacturers for patients at risk. Finally, their main clinical applications are reviewed.

Mathur-de Vré R, Lemort M (1995) Biophysical properties and clinical applications of magnetic resonance imaging contrast agents. Br J Radiol 68:225–247PubMed

Shellock FG, Kanal E (1999) Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 10:477–484PubMed

Brash RB (1992) New directions in the development of MR imaging contrast media. Radiology 183:1–11PubMed

Brash RC, Weinmann HJ, Wesbey GE (1984) Contrast enhanced NMR imaging: animal study using gadolinium-DTPA complex. AJR 142:625–630

Van Beers BE, Gallez B, Pringot J (1997) Contrast-enhanced MR imaging of the liver. Radiology 203:297–306PubMed

Rinck PA, Muller RN (1999) Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol 9:998–1004PubMed

Tweedle MF, Wedeking P, Krishan K (1995) Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 30:372–380PubMed

Oksendal A, Hals P (1993) Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging 3:157–165PubMed

Chang C (1993) Magnetic resonance imaging contrast agents. Designs and physiochemical properties of gadodiamide. Invest Radiol 28 (Suppl 1):521–527

10.

Cacheris W, Quay S, Rocklaye S (1980) The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 8:467–481

11.

Harpur E, Worah D, Hals P et al. (1993) Preclinical safety assessment and pharmacokinetics of gadodiamide injection: a new magnetic resonance imaging contrast agent. Invest Radiol 28:528–543

12.

Tweedle MF, Ealon S, Eckelman W et al. (1988) Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 23 (Suppl 1):236–239

13.

Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 27 (Suppl 1):52–56

14.

Runge VM, Parker JR (1997) Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol 7 (Suppl 5):243–245PubMed

15.

Nelson KI, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA (1995) Clinical safety of gadopentetate dimeglumine. Radiology 2:349–443

16.

Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W (1991) Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 22:222–228PubMed

17.

Kanal E, Applegate G, Gillen C (1990) Review of adverse reactions, including anaphylaxis in 5260 cases receiving gadolinium-DTPA by bolus injection. Radiology 177:159

18.

Tweedle MF (1997) The proHance story: the making of a novel MRI contrast agent. Eur Radiol 7 (Suppl 5):S225–S230

19.

Yuh WTC, Parker JR, Carvlin MJ (1997) Indication-related dosing for resonance contrast media. Eur Radiol 7 (Suppl 5):S269–S275

20.

Yuh WTC, Nguyen HD, Tali ET et al. (1994) Delineation of gliomas with various doses of MR contrast material. Am J Neuroradiol 15:983–989

21.

Prince MR (1998) Contrast-enhanced MR angiography: theory and optimization. Magn Reson Imaging Clin North Am 6:257–267

22.

Haustein J, Laniado M, Niendorf HP et al. (1993) Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186:855–860PubMed

23.

Yuh WTC, Fisher DJ, Engelken JD et al. (1991) MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485–491PubMed

24.

Szopinski K, Szopinska M, Borowka A, Jakubovski W (2000) Magnetic resonance urography: initial experience of a low dose Gd-DTPA-enhanced technique. Eur Radiol 10:1158–1164PubMed

25.

Olukotun AY, Parker JR, Meeks MJ, Lucas MA, Fowler DR, Lucas TR (1995) Safety of gadoteridol injection: US clinical trial experience. J Magn Reson Imaging 5:17–25PubMed

26.

Cohan RH, Leder RA, Herzberg AJ et al. (1991) Extravascular toxicity of two magnetic resonance contrast agents: preliminary experience in the rat. Invest Radiol 26:224–226PubMed

27.

Murphy KJ, Brunberg JA, Cohan RH (1996) Adverse reaction to gadolinium constrast media: a review of 36 cases. AJR 167:847–849

28.

Niendorf HP, Alhassan A, Haustein J, Clauss W, Cornelius I (1993) Safety and risk of gadolinium-DTPA: extended clinical experience after more than 5,000,000 applications. Adv MRI Contrast 2:12–19

29.

Runge VM (2000) Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12:205–213CrossRefPubMed

30.

Eldevik OP, Brunberg JA (1994) Gadopentetate dimeglumine-enhanced MR of brain: clinical utility and safety in patients younger than two years of age. AJNR 15:1001–1008

31.

Hanquiret S, Christope C, Greef DD, Gordon P, Perlemuller N (1996) Clinical evaluation of gadodiamide injection in pediatric MR imaging. Pediatric Radiol 26:806–810

32.

Niess AC, Le Mignon MM, Vitry A, Caille JM (1991) Efficacité et tolérance du DOTA-Gd lors d'une enquête multicentrique européenne. Rev Im Med 3:383–387

33.

Ball WJ, Nadel S, Zimmerman R et al. (1993) Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 186:769–774PubMed

34.

Yoshikawa K, Davies A (1997) Safety of ProHance in special population. Eur Radiol 7 (Suppl 5):246–250CrossRef

35.

Haustein J, Niendorf H, Krestin G et al. (1992) Renal tolerance of gadolinium-DTPA dimeglumine in patients with chronic renal failure. Invest Radiol 27:153–156

36.

Bellin MF, Deray G, Assogba U et al. (1992) Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. Magn Reson Imaging 10:115–118PubMed

37.

Tombach B, Bremer C, Reimer P et al. (2001) Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 218:651–657PubMed

38.

Tombach B, Heindel W (2002) Value of 1.0 M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 12:1550–1556PubMed

39.

Tombach B, Bremer C, Reimer P et al. (2002) Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR 178:105–109PubMed

40.

Schmiedl U, Maravilla K, Gerlach R, Dowling C (1990) Excretion of gadopentetate dimeglumine in human breast milk. AJR 154:1305–1306

41.

Rojski N, Weinreb J, Lih A (1993) Quantitative analysis of gadopentetate dimeglumine excreted in breast milk. J Magn Reson Imaging 3:131–132PubMed

42.

Kubik-Huch RA, Gottstein NM, Frenzel T et al. (2000) Gadopentetate dimeglumine excretion into human breast milk during lactation. Radiology 216:555–558PubMed

43.

Colosimo C, Manfredi R, Tartaglione T (1997) Contrast-enhanced issues in the MR evaluation of the central nervous system. Eur Radiol 7 (Suppl 5):231–237PubMed

44.

Hamm B, Thoeni RF, Gould RG et al. (1994) Focal liver lesions: characterization with nonenhanced and dynamic contrast-material-enhanced MR imaging. Radiology 190:417–423PubMed

45.

Bartolozzi C, Lencioni R, Donati F, Cioni D (1999) Abdominal MR: liver and pancreas. Eur Radiol 9:1496–1512PubMed

46.

Delorme S, Knopp MV (1998) Non-invasive vascular imaging: assessing tumour vascularity. Eur Radiol 8:517–527PubMed

47.

Ho KY, Leiner T, de Haan MW, van Engelshoven JM (1999) Peripheral MR angiography. Eur Radiol 9:1765–1774PubMed

48.

Mahfouz AE, Hamm B, Taupitz M (1997) Contrast agents for MR imaging of the liver: a clinical overview. Eur Radiol 7:507–513CrossRefPubMed

49.

Saeed M, Higgings CB, Geschwind JF, Wendland MF (2000) T1-relaxation kinetics of extracellular, intracellular and intravascular MR agents in normal and acutely reperfused infarcted myocardium using echo-planar MR imaging. Eur Radiol 10:310–318PubMed

50.

Sze G, Stimac GK, Barlett C et al. (1990) Multicenter study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with spinal tumors. AJNR 11:967–974

51.

Yamashita Y, Mitsuzaki K, Yi T et al. (1996) Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology 200:79–84PubMed

52.

Oi H, Mukarami T, Kim T et al. (1996) Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. AJR 166:369–374

53.

Scialpi M, Maggio A di, Midiri M, Loperfido A, Angelelli G, Rotondo A (2000) Small renal masses: assessment of lesion characterization and vascularity on dynamic contrast-enhanced MR imaging with fat suppression. AJR 175:751–757

54.

Balci NC, Semelka RC, Patt RH et al. (1999) Complex renal cysts: findings on MR imaging. AJR 172:1495–1500

55.

Saez F, Urresola A, Larena JA et al. (2000) Endometrial carcinoma: assessment of myometrial invasion with plain and gadolinium-enhanced MR imaging. J Magn Reson Imaging 12:460–466CrossRefPubMed

56.

Kinoshita T, Ishii K, Naganuma H, Higashiiwai H (2000) MR findings of ovarian tumours with cystic components. Br J Radiol 73:333–339PubMed

57.

Barentsz JO, Engelbrecht M, Jager GJ et al. (1999) Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 10:295–304PubMed

58.

Hayashi N, Tochigi H, Shiraishi T, Takeda K, Kawamura J (2000) A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. Br J Urol 85:32–36

59.

Glockner JF (2001) Three-dimensional gadolinium-enhanced MR angiography: applications for abdominal imaging. RadioGraphics 21:357–370PubMed

60.

White-Nunes L, Schnall MD, Orel SG et al. (1999) Correlation of lesion appearance and histologic findings for the nodes of a breast MR imaging interpretation model. RadioGraphics 19:79–92PubMed

61.

Fisher U, Kopka L, Grabbe E (1999) Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic apprach. Radiol 213:881–888PubMed

62.

Hulka CA, Edmister WB, Smith BL et al. (1997) Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837–842PubMed

63.

van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL (1998) Musculoskeletal tumors: Does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology 208:821–828

Titel: Currently used non-specific extracellular MR contrast media
verfasst von: M. F. Bellin
M. Vasile
S. Morel-Precetti
Publikationsdatum: 01.12.2003
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 12/2003
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-003-1912-x

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Currently used non-specific extracellular MR contrast media

Abstract

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2003

The role of ultrasound in the diagnosis, management and evolutive prognosis of acute left-sided colonic diverticulitis: a review of 208 patients

Synchrotron radiation in radiology: novel X-ray sources

Individually weight-adapted examination protocol in retrospectively ECG-gated MSCT of the heart

Acute colonic diverticulitis: CT or ultrasound?

Multi-slice spiral CT in routine diagnosis of suspected acute left-sided colonic diverticulitis: a prospective study of 120 patients

Aneurysmal sizing after endovascular repair in patients with abdominal aortic aneurysm: interobserver variability of various measurement protocols and its clinical relevance

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie